Nancy Gray Net Worth

The estimated Net Worth of Nancy Ryan Gray is at least $1 million dollars as of 9 May 2024. Nancy Gray owns over 934 units of Ligand Pharmaceuticals stock worth over $580,706 and over the last 7 years he sold LGND stock worth over $77,709. In addition, he makes $344,900 as Independent Director at Ligand Pharmaceuticals.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Nancy Gray LGND stock SEC Form 4 insiders trading

Nancy has made over 1 trades of the Ligand Pharmaceuticals stock since 2024, according to the Form 4 filled with the SEC. Most recently he sold 934 units of LGND stock worth $77,709 on 9 May 2024.

The largest trade he's ever made was selling 934 units of Ligand Pharmaceuticals stock on 9 May 2024 worth over $77,709. On average, Nancy trades about 93 units every 0 days since 2017. As of 9 May 2024 he still owns at least 5,633 units of Ligand Pharmaceuticals stock.

You can see the complete history of Nancy Gray stock trades at the bottom of the page.

Nancy Gray biography

Dr. Nancy Ryan Gray Ph.D. serves as Independent Director of the Company. Dr. Gray has acted as the President and CEO of Gordon Research Conferences, a nonprofit organization focused on organizing international scientific conferences, since 2003. From December 1997 until August 2003 she served as the Director of Membership for the American Chemical Society. Prior to that, Dr. Gray worked as a Senior Research Scientist at Exxon/Mobil Research and Engineering, a subsidiary of Exxon Mobil Corporation focused on researching oil and gas. Dr. Gray is a Fellow of the Royal Society of Chemistry, a Fellow of the American Association for the Advancement of Science and a member of the American Chemical Society. She was a Research Fellow at the Foundation on Matter Institute for Atomic and Molecular Physics in Amsterdam, and completed the Harvard Executive Education Finance for Senior Executives program. She also has authored or co-authored numerous scientific articles. Dr. Gray received her B.S. in Chemistry from the University of Notre Dame in 1981 and her Ph.D. in Fuel Science from The Pennsylvania State University in 1985. Dr. Gray’s scientific background and knowledge of the biotechnology industry contributed to our board of directors’ conclusion that she should serve as a director of our company.

What is the salary of Nancy Gray?

As the Independent Director of Ligand Pharmaceuticals, the total compensation of Nancy Gray at Ligand Pharmaceuticals is $344,900. There are 14 executives at Ligand Pharmaceuticals getting paid more, with John Higgins having the highest compensation of $6,770,380.

How old is Nancy Gray?

Nancy Gray is 60, he's been the Independent Director of Ligand Pharmaceuticals since 2017. There are 2 older and 14 younger executives at Ligand Pharmaceuticals. The oldest executive at Ligand Pharmaceuticals, Inc. is John Lamattina, 70, who is the Independent Director.

What's Nancy Gray's mailing address?

Nancy's mailing address filed with the SEC is 555 HERITAGE DRIVE, SUITE 200, JUPITER, FL, 33458.

Insiders trading at Ligand Pharmaceuticals

Over the last 21 years, insiders at Ligand Pharmaceuticals have traded over $205,340,014 worth of Ligand Pharmaceuticals stock and bought 2,116,600 units worth $27,601,439 . The most active insiders traders include Partners L P/Ilbiotechnolog..., Partners L P/Ilbiotechnolog... et Partners L P/Ilbiotechnolog.... On average, Ligand Pharmaceuticals executives and independent directors trade stock every 22 days with the average trade being worth of $2,239,733. The most recent stock trade was executed by Octavio Espinoza on 28 August 2024, trading 753 units of LGND stock currently worth $50,090.

What does Ligand Pharmaceuticals do?

ligand, a pharmaceutical company, is assembling a large and diverse portfolio of current and near-term commercial revenue generating assets to assist the long-term financial growth of the company. we operate this business on a lean cost structure that allows us to maximize cash flow and ultimately deliver a meaningful return for our shareholders.

Complete history of Nancy Gray stock trades at Ligand Pharmaceuticals

Ligand Pharmaceuticals executives and stock owners

Ligand Pharmaceuticals executives and other stock owners filed with the SEC include:

• John Higgins,
  Chief Executive Officer, Director
• Matthew Foehr,
  President, Chief Operating Officer
• Matthew Korenberg,
  Chief Financial Officer, Executive Vice President - Finance
• Charles Berkman,
  Senior Vice President, General Counsel, Secretary
• John L. Higgins,
  CEO & Exec. Director
• Matthew W. Foehr,
  Pres & COO
• Matthew E. Korenberg,
  Exec. VP of Fin. & CFO
• Charles S. Berkman J.D.,
  Sr. VP, Gen. Counsel & Sec.
• Charles S. Berkman,
  Sr. VP, Gen. Counsel & Sec.
• Sarah Boyce,
  Independent Director
• John Kozarich,
  Non-Executive Independent Chairman of the Board
• Stephen Sabba,
  Independent Director
• Jason Aryeh,
  Independent Director
• Todd Davis,
  Independent Director
• Sunil Patel,
  Independent Director
• Nancy Gray,
  Independent Director
• John Lamattina,
  Independent Director
• Simon Latimer,
  Head of Investor Relations
• Patrick Lucy,
  Sr. VP & CBO Protein Expression Bus.
• Dr. Vincent D. Antle,
  Sr. VP of Technical Operations & QA - Capitsol
• Dr. Keith Marschke,
  Sr. VP of Biology & Scientific Affairs
• Audrey Warfield-Graham,
  Sr. VP of HR
• Todd Pettingill,
  Director of Corp. Devel.
• Patrick O'Brien,
  Sr. VP of Investor Relations
• Jason Haas,
  Director
• Corp Plc Elan,
  10% owner
• Andres Negro Vilar,
  Exe V-P, R & D, CSO
• Partners L P/Ilbiotechnolog...,
  
• Bruce Peacock,
  Director
• Zofia E Dziewanowska,
  VP, Clinical Research
• Partners L P/Ilbiotechnolog...,
  
• Melanie J Herman,
  Director of Accounting
• Nishan M De Silva,
  VP, Corporate Development
• David M Knott,
  10% owner
• Syed Kazmi,
  VP, Bus. Dev. & Strategic Plan
• Martin Meglasson,
  V-P, Discovery Research
• Pharmaceuticals Inc Ligand,
  Director
• Partners L P/Ilbiotechnolog...,
  
• Partners L P/Ilbiotechnolog...,
  
• Partners L P/Ilbiotechnolog...,
  
• Steven J Burakoff,
  Director
• Brigette Roberts,
  Director
• Partners L P/Ilbiotechnolog...,
  
• John P Sharp,
  VP Finance and CFO
• Daniel S Loeb,
  Director
• Michael A Rocca,
  Director
• John Groom,
  Director
• Taylor Crouch,
  Sr. V-P, Ops & Pres. Int'l
• Partners L P/Ilbiotechnolog...,
  
• Jeffrey R Perry,
  Director
• Alexander D Cross,
  Director
• William A Petttit,
  Sr. V-P, HR and Administration
• Paul V Maier,
  Sr. V-P, CFO
• Warner R Broaddus,
  V-P, Gen. Counsel & Secy.
• Elizabeth M Greetham,
  Director
• Henry F Blissenbach,
  Director
• Irving S Johnson,
  Director
• Carl C Peck,
  Director
• Eric S Groves,
  V-P, Project Management
• Giambattista Aliprandi,
  Sr. VP, Tech., Sup & Intl Oper
• James J Litalien,
  Sr. V-P, Reg Affairs & Comp.
• David E Robinson,
  President & CEO
• Tod Mertes,
  V-P, Controller & Treasurer
• Jennifer R. Cochran,
  
• Octavio Espinoza,
  Chief Financial Officer
• Martine Zimmermann,
  Director
• Andrew Reardon,
  CLO & Secretary